Analyst Activity: Jamf Buy Rating, Fortrea EPS Lowered

Recent analyst activity includes a buy rating for Jamf and lowered earnings estimates for Fortrea, Verisk, Teladoc Health, and VSE, all involving insights from William Blair. CentralReach is also exploring a sale with William Blair's assistance.

Analyst Activity: Jamf Buy Rating, Fortrea EPS Lowered

The world of finance is constantly in motion, with analysts providing valuable insights into the performance and potential of various companies. Here's a brief overview of recent analyst activity, focusing on ratings and earnings estimates.

Jamf Receives Buy Rating

Needham & Company LLC reiterated their buy rating on shares of Jamf (NASDAQ:JAMF) in a research report published on Tuesday. The firm currently has a $25.00 target price on the stock. Other analysts, including William Blair, have also weighed in positively on Jamf.

Chart showing Jamf stock performance with an upward trend.

This positive outlook suggests confidence in Jamf's future performance. Investors often look to these ratings as indicators of potential investment opportunities. A "buy" rating generally indicates that analysts believe the stock is undervalued and likely to increase in price.

Earnings Estimates Adjusted

Several companies have seen adjustments to their earnings per share (EPS) estimates from William Blair. These revisions offer insight into potential future financial performance.

Fortrea Holdings Inc. (NASDAQ:FTRE) had its Q4 2025 EPS estimate lowered by William Blair analyst M. Smock, from $0.47 to $0.39. Verisk Analytics, Inc. (NASDAQ: VRSK) also saw a decrease in its Q1 2025 EPS estimates, with analyst A. Nicholas now anticipating $1.66 per share. In addition, William Blair decreased their Q1 2025 earnings per share estimates for shares of Teladoc Health (NYSE:TDOC), with analyst R. Daniels now forecasting that the health services provider will post earnings per share of ($0.31) for the quarter. Similarly, William Blair issued their Q1 2025 EPS estimates for VSE Co. (NASDAQ:VSEC), with analyst L. Dipalma anticipating earnings of $0.97 per share for the quarter.

A graph showing downward trending lines representing lowered EPS estimates.

Lowered EPS estimates can sometimes signal potential challenges for a company, while newly issued estimates provide a benchmark for investors to consider.

CentralReach Exploring a Sale

CentralReach, an autism care software company, is reportedly exploring a sale, with William Blair engaged to assist in the process. Multiple sources with knowledge of the situation have indicated that the company is seeking potential buyers.

This move could indicate a strategic shift for CentralReach, or simply an opportunity for its current owners to realize a return on their investment.

"Analyst ratings and earnings estimates play a crucial role in investor decision-making, providing valuable insights into a company's financial health and future prospects," says a financial analyst.
A group of analysts discussing financial data around a conference table.

Staying informed about these activities is essential for anyone involved in the stock market. Remember to consult with a financial advisor before making any investment decisions.

Share this article: